Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 1

Status

Active not recruiting 3Recruiting 2Completed 2

Sponsor Class

OTHER 4NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Genitourinary 7

Conditions

Prostatic Neoplasms 5Metastatic Castration-resistant Prostate Cancer 1Biochemical Recurrent Prostate Cancer 1

Interventions

Magnetic Resonance Spectroscopy 98Specimen Handling 79pembrolizumab 75enzalutamide 63Nivolumab 59Gemcitabine 54Docetaxel 50apalutamide 42Radiosurgery 41Abiraterone Acetate 40Androgen Antagonists 39Prednisone 38Biopsy 37darolutamide 35Cisplatin 35cabozantinib 31Radiotherapy 31Carboplatin 28Pluvicto 27abiraterone 26enfortumab vedotin 24Ipilimumab 24Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 18X-Rays 18Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Radium-223 × Genitourinary × 90 days × Clear all
NCT04109729 2026-06-01

Rad2Nivo

University of Utah

Phase 1 Active not recruiting
39 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07611110 2026-05-28

VECTRA-01

AstraZeneca

Phase 3 Recruiting
670 enrolled
Genitourinary

Prostatic Neoplasms

NCT03574571 2026-05-14

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 3 Active not recruiting
732 enrolled
Genitourinary

Prostatic Neoplasms

NCT05133440 2026-04-28

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
12 enrolled
Genitourinary

Prostatic Neoplasms

NCT02225704 2026-04-13

Radium-223 in Combination With Enzalutamide

Cancer Trials Ireland

Phase 2 Completed
45 enrolled
Genitourinary

Prostatic Neoplasms

NCT06389097 2026-03-30

(SEEtoTREAT)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Recruiting
80 enrolled
Genitourinary

Prostatic Neoplasms

NCT04206319 2026-03-16

Radium-223 in Biochemically Recurrent Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
19 enrolled
Genitourinary

Biochemical Recurrent Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡